Compulsory Licensing: EU Council Backs Stronger IP Protections
Executive Summary
The R&D-based pharma industry has welcomed the “more careful and considered approach” taken by EU ministers to the European Commission’s proposed compulsory licensing system, but says there is room for further improvement.